Abstract:Abstract An established tumor is a complex tissue composed of tumor cells, stromal cells, inflammatory cells, vasculatures, and extracellular matrices, all of which are defined together as the tumor microenvironment. Successful tumor control by immunotherapy requires activation of the immune system, expansion of the effector cells, infiltration of activated effector cells to the tumor tissue, and destruction of the tumor cells. Our previous studies have showed that anti-tumor effect of current tumor immunotherapies, such as checkpoint blockade, relies on a significant number of spontaneous tumor infiltrating lymphocytes. However, established tumors often inhibit peripheral lymphocytes entering tumor tissues for tumor destruction. Inflammatory mediators, especially cytokines, chemokines, and adhesion molecules, play important roles in the recruitment and activation of various types of innate and adaptive immune cells. As a proof-of-concept study, we targeted tumor tissues with LIGHT, a member of the tumor necrosis factor super family. Our data suggested that targeting tumor with LIGHT is able to induce the production of several cytokines/chemokines, which recruit T cells into tumor microenvironment, leading to tumor regression. Furthermore, combination therapy with LIGHT is able to overcome tumor resistance to checkpoint blockade. Thus, these data suggested that manipulating tumor microenvironment with cytokines/chemokines that are able to recruit effector cells represents a promising strategy for tumor immunotherapy. To better understand the role of individual cytokine/chemokine, we utilized chemokine array to systemically analyze tumor microenvironments. By comparing chemokine profiles from immunotherapy-sensitive and -insensitive tumors, we found a significant difference which might be responsible for their sensitivity to immunotherapies. Sensitive tumor is characterized with a higher level of chemokines associated with lymphoid cell trafficking, such as CXCL9 and CCL22. In contrast, insensitive tumor is characterized by a higher levels of chemokines associated with myeloid cell, such as MCP-1 and CCL11. The contributions and their therapeutic potentials of these cytokines/chemokines will be studied in the next step. Citation Format: Haidong Tang, Xiangyan Qiu, Yang Wang, Yang-Xin Fu. Manipulating tumor microenvironment for immunotherapy [abstract]. In: Proceedings of the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; 2016 Sept 25-28; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2016;4(11 Suppl):Abstract nr A112.

From Biomarkers to Therapeutic Targets

Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.

Cytokines and soluble mediators as architects of tumor microenvironment reprogramming in cancer therapy

Novel chemokine biomarkers in melanomaâ€

Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response

Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma

Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy

Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade

Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression

The paradoxical role of cytokines and chemokines at the tumor microenvironment: a comprehensive review

Cytokines That Target Immune Killer Cells Against Tumors

Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy

Targeting cytokine and chemokine signaling pathways for cancer therapy

Data from Facts and Hopes on Chimeric Cytokine Agents for Cancer Immunotherapy

Chemokine Receptors and Exercise to Tackle the Inadequacy of T Cell Homing to the Tumor Site

Abstract A112: Manipulating Tumor Microenvironment for Immunotherapy

Roles of the CXCL8-CXCR1/2 Axis in the Tumor Microenvironment and Immunotherapy

Unbiased chemokine receptor screening reveals similar efficacy of lymph node- and tumor-targeted T cell immunotherapy

The Chemokine CXCL14 as a Potential Immunotherapeutic Agent for Cancer Therapy

Role of chemokines in the crosstalk between tumor and tumor-associated macrophages